Authors
Moritz Meusel, Henry Nording, Oliver Müller
Published in
Deutsche medizinische Wochenschrift (1946). Volume 151. Issue 22. Pages 1207-1212. Epub Nov 02, 2026.
Abstract
Venous thrombosis at unusual sites such as the upper extremity, the splanchnic and cerebral veins, and rarer ovarian, renal and retinal sites has long been managed in analogy to lower-limb deep vein thrombosis because dedicated trials were lacking. This has changed substantially. The 2023 German S2k guideline now addresses these sites explicitly, and a growing body of randomized and prospective evidence supports the use of direct oral anticoagulants (DOACs). For upper-extremity thrombosis, therapeutic anticoagulation is first-line and is managed according to deep vein thrombosis. A functioning, still-needed catheter can remain in situ. For splanchnic vein thrombosis, anticoagulation reduces recurrence and mortality and improves recanalization, including in cirrhotic portal vein thrombosis (Child-Pugh A/B). In cirrhotic portal vein thrombosis DOACs are possible depending on the liver function (rivaroxaban/edoxaban in Child A, apixaban in Child B, low molecular weight heparin in Child C). A JAK2-V617F screen identifies an underlying myeloproliferative neoplasm before blood-count changes appear and should be part of the etiological work-up of a non-cirrhotic splanchnic vein thrombosis. For cerebral venous thrombosis, DOACs have shown to be as effective as vitamin K antagonists with fewer major, particularly intracranial, bleeds, while vaccine-induced immune thrombotic thrombocytopenia (VITT) requires non-heparin anticoagulation. For ovarian, renal and retinal veins, robust data remains absent. This article summarizes the practice-relevant advances for the general internist, focusing on the upper extremity and the splanchnic veins.
PMID:
42971238
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0